{"id":17312,"date":"2020-06-04T20:15:39","date_gmt":"2020-06-04T19:15:39","guid":{"rendered":"http:\/\/dev5.sclerodermie.ca\/?page_id=17312"},"modified":"2022-02-25T21:10:47","modified_gmt":"2022-02-25T20:10:47","slug":"news","status":"publish","type":"page","link":"http:\/\/dev5.sclerodermie.ca\/en\/home\/news\/","title":{"rendered":"News"},"content":{"rendered":"

Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV\u00ae (nintedanib) for PF-ILD<\/span><\/h1>\n
BURLINGTON, ON, February 15, 2022<\/strong> – Boehringer Ingelheim (Canada) Ltd. and the pan-Canadian Pharmaceutical Alliance (pCPA) have completed negotiations for OFEV\u00ae (nintedanib), a multi-targeted tyrosine kinase inhibitor for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as PF-ILD).1<\/sup><\/div>\n

Read more<\/span><\/span><\/strong><\/a><\/p>\n

\n

OPSYNVI\u00ae (macitentan and tadalafil) Becomes the First and Only Health Canada-Approved Once Daily Fixed Dose Combination Treatment for Patients with Pulmonary Arterial Hypertension (PAH)<\/span><\/h1>\n
TORONTO<\/span>, Oct. 15, 2021<\/span><\/strong> \/CNW\/ – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada approved OPSYNVI\u00ae<\/sup>\u00a0(macitentan 10mg and tadalafil 40mg) for the long-term treatment of pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to reduce morbidity in patients of WHO functional class (FC) II or III whose PAH is idiopathic, heritable, or associated with connective tissue disease or congenital heart disease.<\/div>\n
\n

OFEV\u00ae (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of <\/span>progressive fibrosing interstitial lung diseases (PF-ILD)<\/span><\/h1>\n
BURLINGTON, ON, March 4, 2021<\/strong> \/CNW\/ \u2013 Boehringer Ingelheim (Canada) Ltd. is pleased to announce positive recommendations from the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institut national d’excellence en sant\u00e9 et services sociaux (INESSS) for OFEV\u00ae (nintedanib) for the treatment of chronic fibrosing interstitial lung diseases with a progressive phenotype (also known as PF-ILD) when certain conditions are met.<\/div>\n

Read more<\/span><\/span><\/strong><\/span><\/a><\/p>\n

\n

Launch of Scleroderma Quebec’s summer funding campaign<\/span><\/h1>\n
June is scleroderma awareness month in Canada and the Unites States. It is a privileged time to inform and raise awareness of the general public on the existence of this little-known and orphan disease and the capital importance of research to find a curative treatment. On this occasion, Scleroderma Quebec launches the \u201cDemystify scleroderma\u201d campaign. Share in large numbers!<\/div>\n

 <\/p>\n

SHARE ON YOUR SOCIAL MEDIAS<\/a><\/span><\/span><\/p>\n

<\/p>\n

\n

OFEV\u00ae (nintedanib) now available in Canada for progressive fibrotic interstitial lung diseases (PF-ILD)<\/span><\/h1>\n
BURLINGTON, ON, May 25, 2020<\/strong> \/CNW\/ \u2013 Boehringer Ingelheim (Canada) Ltd. announced today that OFEV\u00ae (nintedanib) is authorized for sale by Health Canada for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as progressive fibrosing ILD).<\/div>\n
Read more<\/span><\/span><\/strong><\/span><\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV\u00ae (nintedanib) for PF-ILD BURLINGTON, ON, February 15, 2022 – Boehringer Ingelheim (Canada) Ltd. and the pan-Canadian Pharmaceutical Alliance (pCPA) have completed negotiations for OFEV\u00ae (nintedanib), a multi-targeted tyrosine kinase inhibitor for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a […]<\/p>\n","protected":false},"author":5,"featured_media":0,"parent":7,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-salle-des-medias2.php","meta":[],"acf":[],"yoast_head":"\nNews - Sclerodermie<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/dev5.sclerodermie.ca\/en\/home\/news\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"News - Sclerodermie\" \/>\n<meta property=\"og:description\" content=\"Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV\u00ae (nintedanib) for PF-ILD BURLINGTON, ON, February 15, 2022 – Boehringer Ingelheim (Canada) Ltd. and the pan-Canadian Pharmaceutical Alliance (pCPA) have completed negotiations for OFEV\u00ae (nintedanib), a multi-targeted tyrosine kinase inhibitor for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a […]\" \/>\n<meta property=\"og:url\" content=\"http:\/\/dev5.sclerodermie.ca\/en\/home\/news\/\" \/>\n<meta property=\"og:site_name\" content=\"Sclerodermie\" \/>\n<meta property=\"article:modified_time\" content=\"2022-02-25T20:10:47+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/dev5.sclerodermie.ca\/wp-content\/uploads\/2020\/06\/ANG_SCLQ02_moisSclerodermie_facebook_couverture_851x315.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/dev5.sclerodermie.ca\/en\/home\/news\/\",\"url\":\"http:\/\/dev5.sclerodermie.ca\/en\/home\/news\/\",\"name\":\"News - Sclerodermie\",\"isPartOf\":{\"@id\":\"http:\/\/dev5.sclerodermie.ca\/#website\"},\"datePublished\":\"2020-06-04T19:15:39+00:00\",\"dateModified\":\"2022-02-25T20:10:47+00:00\",\"breadcrumb\":{\"@id\":\"http:\/\/dev5.sclerodermie.ca\/en\/home\/news\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/dev5.sclerodermie.ca\/en\/home\/news\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/dev5.sclerodermie.ca\/en\/home\/news\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"http:\/\/dev5.sclerodermie.ca\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Discover our website\",\"item\":\"http:\/\/dev5.sclerodermie.ca\/en\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News\"}]},{\"@type\":\"WebSite\",\"@id\":\"http:\/\/dev5.sclerodermie.ca\/#website\",\"url\":\"http:\/\/dev5.sclerodermie.ca\/\",\"name\":\"Sclerodermie\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"http:\/\/dev5.sclerodermie.ca\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"News - Sclerodermie","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/dev5.sclerodermie.ca\/en\/home\/news\/","og_locale":"en_US","og_type":"article","og_title":"News - Sclerodermie","og_description":"Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV\u00ae (nintedanib) for PF-ILD BURLINGTON, ON, February 15, 2022 – Boehringer Ingelheim (Canada) Ltd. and the pan-Canadian Pharmaceutical Alliance (pCPA) have completed negotiations for OFEV\u00ae (nintedanib), a multi-targeted tyrosine kinase inhibitor for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a […]","og_url":"http:\/\/dev5.sclerodermie.ca\/en\/home\/news\/","og_site_name":"Sclerodermie","article_modified_time":"2022-02-25T20:10:47+00:00","og_image":[{"url":"http:\/\/dev5.sclerodermie.ca\/wp-content\/uploads\/2020\/06\/ANG_SCLQ02_moisSclerodermie_facebook_couverture_851x315.jpg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/dev5.sclerodermie.ca\/en\/home\/news\/","url":"http:\/\/dev5.sclerodermie.ca\/en\/home\/news\/","name":"News - Sclerodermie","isPartOf":{"@id":"http:\/\/dev5.sclerodermie.ca\/#website"},"datePublished":"2020-06-04T19:15:39+00:00","dateModified":"2022-02-25T20:10:47+00:00","breadcrumb":{"@id":"http:\/\/dev5.sclerodermie.ca\/en\/home\/news\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/dev5.sclerodermie.ca\/en\/home\/news\/"]}]},{"@type":"BreadcrumbList","@id":"http:\/\/dev5.sclerodermie.ca\/en\/home\/news\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"http:\/\/dev5.sclerodermie.ca\/en\/"},{"@type":"ListItem","position":2,"name":"Discover our website","item":"http:\/\/dev5.sclerodermie.ca\/en\/"},{"@type":"ListItem","position":3,"name":"News"}]},{"@type":"WebSite","@id":"http:\/\/dev5.sclerodermie.ca\/#website","url":"http:\/\/dev5.sclerodermie.ca\/","name":"Sclerodermie","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"http:\/\/dev5.sclerodermie.ca\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"http:\/\/dev5.sclerodermie.ca\/en\/wp-json\/wp\/v2\/pages\/17312"}],"collection":[{"href":"http:\/\/dev5.sclerodermie.ca\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/dev5.sclerodermie.ca\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/dev5.sclerodermie.ca\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"http:\/\/dev5.sclerodermie.ca\/en\/wp-json\/wp\/v2\/comments?post=17312"}],"version-history":[{"count":41,"href":"http:\/\/dev5.sclerodermie.ca\/en\/wp-json\/wp\/v2\/pages\/17312\/revisions"}],"predecessor-version":[{"id":23955,"href":"http:\/\/dev5.sclerodermie.ca\/en\/wp-json\/wp\/v2\/pages\/17312\/revisions\/23955"}],"up":[{"embeddable":true,"href":"http:\/\/dev5.sclerodermie.ca\/en\/wp-json\/wp\/v2\/pages\/7"}],"wp:attachment":[{"href":"http:\/\/dev5.sclerodermie.ca\/en\/wp-json\/wp\/v2\/media?parent=17312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

Read more<\/span><\/span><\/strong><\/a><\/p>\n